```
=> s l1
SAMPLE SEARCH INITIATED 16:26:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      763 TO ITERATE

100.0% PROCESSED      763 ITERATIONS                                 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        13603 TO     16917
PROJECTED ANSWERS:               5 TO       234

L2            5 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 16:26:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    15491 TO ITERATE

100.0% PROCESSED    15491 ITERATIONS                               107 ANSWERS
SEARCH TIME: 00.00.01

L3          107 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.57

FILE 'CAPLUS' ENTERED AT 16:26:36 ON 06 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Jan 2008  VOL 148 ISS 2
FILE LAST UPDATED: 4 Jan 2008  (20080104/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            9 L3

=> d l4 1-9 fhitstr
```

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of aminophenylsulfonylquinolines from fluorophenylsulfonylquinolines and amines in the presence of base and solvent)
RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 927891-10-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoquinolines and related compds. 5-ht5 receptor inhibitors)
RN 927891-10-9 CAPLUS
CN 2-Quinolinamine, 3-[(2-methoxyphenyl)methyl]-6-(4-methyl-1-piperazinyl)-, 2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 927891-09-6
CMF C22 H26 N4 O



CM 2

CRN 6915-18-0
CMF C4 H4 O4

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 607743-50-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of isotopomeric piperazine-containing ligands labeling and
diagnostic imaging of 5-HT6 receptors)
RN 607743-50-0 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline)
RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 849586-10-3P, 3-[(3-Chlorophenyl)methyl]-8-(1-

piperazinyl)quinoline monohydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinyl-quinolines for treating CNS disorders)
RN 849586-10-3 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)methyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 848396-13-4P, 8-[4-(4-Fluorobenzyl)piperazin-1-yl]-3-phenylsulfonylquinoline
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)
RN 848396-13-4 CAPLUS
CN Quinoline, 8-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 847727-11-1P, 3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(1-piperazinyl)quinoline monohydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of piperazinylquinolines for treatment of CNS disorders)
RN 847727-11-1 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 636997-89-2P, tert-Butyl 4-[3-[(4-tert-butylphenyl)thio]quinolin-5-yl]-1,4-diazepane-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphthelene and pyridino-fused heterocycles useful for the treatment of obesity, type II diabetes and CNS disorders)
RN 636997-89-2 CAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[3-[[4-(1,1-dimethylethyl)phenyl]thio]-5-quinolinyl]hexahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 607743-10-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)
RN 607743-10-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-(phenylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



```
=> d l4 1-9 bib abs fhitstr

L4   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:410374  CAPLUS
DN   146:402011
TI   Process for preparation of 8-amino-3-phenylsulfonylquinolines from
     8-fluoro-3-phenylsulfonylquinoline and amines in the presence of base and
     solvent.
IN   Wade, Charles Edward
PA   Glaxo Group Limited, UK
SO   PCT Int. Appl., 26pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2007039238        A1     20070412    WO 2006-EP9460         20060926
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRAI GB 2005-19758        A     20050928
OS   CASREACT 146:402011; MARPAT 146:402011
GI
```



I

```
AB   Title compds. [I; R1, R2 = H, alkyl; NR1R2 = (substituted) 4-7 membered
     heterocyclyl], were prepared by reaction of 8-fluoro-3-
     phenylsulfonylquinoline with R1R2NH (variables as above) in the presence
     of base and solvent.  Thus, 8-fluoro-3-phenylsulfonylquinoline (preparation
     given), piperazine, and K2CO3 were heated together in n-propanol at
     100° for 23 h to give 86% 3-phenylsulfonyl-8-piperazin-1-
     ylquinoline.  Polymorphic forms II and III of the latter were prepared via
     recrystn.
IT   607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline
     RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
```

(Preparation)
(preparation of aminophenylsulfonylquinolines from fluorophenylsulfonylquinolines and amines in the presence of base and solvent)

RN 607742-69-8 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:226817 CAPLUS

DN 146:295780

TI Preparation of 2-aminoquinolines and related compounds 5-ht5 receptor inhibitors

IN Amberg, Wilhelm; Netz, Astrid; Kling, Andreas; Ochse, Michael; Lange, Udo; Hutchins, Charles W.; Garcia-Ladona, Francisco Javier; Wernet, Wolfgang

PA Abbott G.m.b.H. & Co. K.-G., Germany

SO PCT Int. Appl., 298pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022946	A1	20070301	WO 2006-EP8222	20060821
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	DE 2005-102005040602 A		20050821		
	US 2005-711075P P		20050824		
	DE 2006-102006005916 A		20060209		

OS MARPAT 146:295780

GI



I



II

AB Title compds. I [R1, R2 = H, electron lone pair, OH, etc.; R3 = H, NO2, NH2, etc.; R4 = a bond in a ring to X5 with provisos; R5 = H, lone electron pair, O-alkyl, etc.; R6, R7, R8, R9 = free electron lone pair or N or C with provisos, etc.; W = substituted phenyl; Z = (CRz1Rz2)a; Rz1, Rz2 = H, halo, OH, etc.; X5 = C, N; X1 = C, N; X2 = C, N; X3 = C, N; X4 = C, N] and their pharmaceutically acceptable salts were prepared For example, aminoquinoline II was prepared from 2-chloroquinoline in 3-steps. In 5-HT5a receptor binding assays, 80-examples of compds. I exhibited Ki values ≤ 300nM.

IT 927891-10-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoquinolines and related compds. 5-ht5 receptor inhibitors)

RN 927891-10-9 CAPLUS

CN 2-Quinolinamine, 3-[(2-methoxyphenyl)methyl]-6-(4-methyl-1-piperazinyl)-, 2-butenedioate (1:2) (CA INDEX NAME)

CM 1

CRN 927891-09-6
CMF C22 H26 N4 O



CM 2

CRN 6915-18-0
CMF C4 H4 O4



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:493996 CAPLUS
DN 145:8187
TI Preparation of isotopomeric piperazine-containing ligands labeling and diagnostic imaging of 5-HT6 receptors
IN Gee, Antony David; Martarello, Laurent; Johnson, Christopher Norbert; Witty, David R.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006053785	A1	20060526	WO 2005-EP12463	20051117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2588381	A1	20060526	CA 2005-2588381	20051117
EP 1824830	A1	20070829	EP 2005-807786	20051117
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
PRAI GB 2004-25548	A	20041119		
WO 2005-EP12463	W	20051117		

OS CASREACT 145:8187; MARPAT 145:8187
GI



I

AB Piperazine-containing ligands [I; R1 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; R2 = F; or R1 = C1-4 (fluoro)alkyl and R2 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; e.g., (11C-N-methyl)-3-[(3-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline; 5-HT6 receptor pKi 9.82], which are useful for the labeling and diagnostic imaging of 5-HT6 receptors functionality and the treatment of CNS related disorders, are prepared

IT 607743-50-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of isotopomeric piperazine-containing ligands labeling and
diagnostic imaging of 5-HT6 receptors)

RN 607743-50-0 CAPLUS

CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:395276 CAPLUS

DN 142:430310

TI Process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline

IN Gladwin, Asa Elisabeth

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040124	A1	20050506	WO 2004-EP10843	20040923
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004283805	A1	20050506	AU 2004-283805	20040923
	CA 2540022	A1	20050506	CA 2004-2540022	20040923
	EP 1667975	A1	20060614	EP 2004-765655	20040923
	EP 1667975	B1	20071128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1856471	A	20061101	CN 2004-80027527	20040923
	BR 2004014678	A	20061128	BR 2004-14678	20040923
	JP 2007506702	T	20070322	JP 2006-527373	20040923
	IN 2006DN00970	A	20070817	IN 2006-DN970	20060224
	US 2007032504	A1	20070208	US 2006-572670	20060320
	MX 2006PA03375	A	20060608	MX 2006-PA3375	20060324
	KR 2007020372	A	20070221	KR 2006-705895	20060324
	NO 2006001791	A	20060424	NO 2006-1791	20060424
PRAI	GB 2003-22629	A	20030926		
	WO 2004-EP10843	W	20040923		

OS CASREACT 142:430310

AB Polymorphic crystalline forms of 3-phenylsulfonyl-8-piperazin-1-ylquinoline are synthesized, characetrized, and claimed in the treatment of CNS (e.g., schizophrenia) and other disorders.

IT 607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline)

RN 607742-69-8 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:300407 CAPLUS
DN 142:373864
TI Preparation of piperazinyl-quinoline derivatives useful for the treatment of CNS disorders
IN Johnson, Christopher Norbert; Moss, Stephen Frederick; Witty, David R.
PA Glaxo Group Limited, UK; Witty, David R
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030724	A1	20050407	WO 2004-EP10845	20040923
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663981	A1	20060607	EP 2004-787037	20040923
	EP 1663981	B1	20070718		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007506704	T	20070322	JP 2006-527375	20040923
	AT 367380	T	20070815	AT 2004-787037	20040923
	US 2007027139	A1	20070201	US 2006-572671	20060320
PRAI	GB 2003-22510	A	20030925		
	WO 2004-EP10845	W	20040923		

OS CASREACT 142:373864; MARPAT 142:373864
GI



I



II

AB The title compds. I [R1 = H, alkyl, alkylaryl, etc.; R2 = H, alkyl; m = 1-4; R3-R5 = H, halo, CN, etc.; n = 1-3; p = 1-2; J = CH2, CO, O, etc.; A = (un)substituted (hetero)aryl] and their pharmaceutically acceptable salts, useful in the treatment of CNS and other disorders such as depression, anxiety, etc., were prepared E.g., a multi-step synthesis of II.HCl, starting from 8-chloroquinoline, was given. Three exemplified compds. I were tested and showed affinity for the 5-HT6 receptor, having pKi values > 6.0 at human cloned 5-HT6 receptors. More particularly, the compound II exhibited pKi > 7.5. The pharmaceutical composition comprising the compound I is claimed.

IT 849586-10-3P, 3-[(3-Chlorophenyl)methyl]-8-(1-piperazinyl)quinoline monohydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinyl-quinolines for treating CNS disorders)

RN 849586-10-3 CAPLUS

CN Quinoline, 3-[(3-chlorophenyl)methyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:260030 CAPLUS
DN 142:336394
TI Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders
IN Johnson, Christopher Norbert; Witty, David R.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026125	A1	20050324	WO 2004-EP10129	20040909
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663980	A1	20060607	EP 2004-765057	20040909
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007505075	T	20070308	JP 2006-525773	20040909
	US 2006287334	A1	20061221	US 2006-571405	20060310
PRAI	GB 2003-21473	A	20030912		
	WO 2004-EP10129	W	20040909		

OS CASREACT 142:336394; MARPAT 142:336394
GI



I



II

AB Title compds. I [R1 = (un)substituted alkyl, alkylcycloalkyl, alkoxyalkyl, alkyl(hetero)aryl, alkylheterocyclyl; R2 = H or alkyl; m = 1-4; when m > 1, two R2 groups may be linked to form a CH2, (CH2)2 or (CH2)3 group; R3-R5 = independently H, halo, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, CONH2 and derivs.; n = 1 - 3; p = 1-2; and their pharmaceutically acceptable salts] were prepared as 5HT6 receptor antagonists in treatment of CNS disorders. Thus, condensation of 3-phenylsulfonyl-8-(piperazin-1-yl)quinoline (preparation given) with 4-fluorobenzaldehyde gave II. I were tested and showed good affinity for the 5-HT6 receptor, having pKi values ≥ 7.0 at human cloned 5-HT6 receptors.

IT 848396-13-4P, 8-[4-(4-Fluorobenzyl)piperazin-1-yl]-3-phenylsulfonylquinoline
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)

RN 848396-13-4 CAPLUS

CN Quinoline, 8-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:216810 CAPLUS

DN 142:298134

TI Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders

IN Johnson, Christopher Norbert; Moss, Stephen Frederick; Tait, Malcolm M.; Witty, David R.

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005021530	A1	20050310	WO 2004-EP9724	20040826
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1660483	A1	20060531	EP 2004-764687	20040826
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007504114	T	20070301	JP 2006-524347	20040826
PRAI	GB 2003-20320	A	20030829		
	WO 2004-EP9724	W	20040826		
OS	MARPAT 142:298134				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, (un)substituted cyclo/alkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl; R2 = H, alkyl; m = 1-4; when m > 1, two R2 groups may be linked to form a CH2, (CH2)2 or (CH2)3 group; when R1 = alkyl, R1 may optionally be linked to R2 to form a (CH2)2, (CH2)3 or (CH2)4 group; R3, R4, R5 = independently H, halo, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, CONH2 and derivs.; n = 1 - 3; X = (CH2)p; p = 1-2; Ra = H, alk(en)yl, alkyl/cycloalkyl; Rb = H, alkyl, (un)substituted alkylaryl, alkylheteroaryl; or RaNRb = (un)substituted heterocyclyl; and their pharmaceutically acceptable salts] were prepared for use as 5HT6 receptor antagonists in treatment of CNS disorders. Thus, II•HCl was prepared by oxidation of 8-chloro-3-quinolinethiol (preparation given), oxidative cleavage of disulfide, amination of the chloride with 1,1-dimethylethyl 1-piperazinecarboxylate and Boc-deprotection. I were tested and showed good affinity for the 5-HT6 receptor, having pKi values ≥ 7.5 at human cloned 5-HT6 receptors.

IT 847727-11-1P, 3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(1-piperazinyl)quinoline monohydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of piperazinylquinolines for treatment of CNS disorders)

RN 847727-11-1 CAPLUS

CN 1H-Indole, 2,3-dihydro-1-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:2873 CAPLUS
DN 140:42036
TI Preparation of pyridino-fused heterocycles useful for the treatment of obesity, type II diabetes and CNS disorders
IN Johansson, Gary; Jenmalm-Jensen, Annika; Beierlein, Katarina
PA Biovitrum AB, Swed.
SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000828	A1	20031231	WO 2003-SE1061	20030619
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2486989	A1	20031231	CA 2003-2486989	20030619
	AU 2003243091	A1	20040106	AU 2003-243091	20030619
	US 2004024210	A1	20040205	US 2003-465034	20030619
	EP 1513828	A1	20050316	EP 2003-760999	20030619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003011952	A	20050419	BR 2003-11952	20030619
	CN 1662521	A	20050831	CN 2003-814432	20030619
	JP 2005536551	T	20051202	JP 2004-530936	20030619
	ZA 2004009030	A	20060222	ZA 2004-9030	20030619

	CN 1907982	A	20070207	CN 2006-10108036	20030619
	NZ 536600	A	20070831	NZ 2003-536600	20030619
	CN 101081845	A	20071205	CN 2006-10101528	20030619
	MX 2004PA12914	A	20050331	MX 2004-PA12914	20041217
	IN 2004CN03052	A	20060217	IN 2004-CN3052	20041231
	NO 2005000294	A	20050204	NO 2005-294	20050119
	IN 2007CN02849	A	20071012	IN 2007-CN2849	20070627
PRAI	SE 2002-1925	A	20020620		
	SE 2002-2181	A	20020711		
	US 2002-406120P	P	20020826		
	SE 2002-2908	A	20021001		
	US 2002-434010P	P	20021217		
	SE 2003-357	A	20030210		
	US 2003-464701P	P	20030423		
	CN 2003-814432	A3	20030619		
	WO 2003-SE1061	W	20030619		
	IN 2004-CN3052	A3	20041231		
OS	MARPAT 140:42036				
GI					



I



II

AB Title compds. I [ring B = same as ring A, 5-membered (un)substituted heterocycle/heteroaryl; W = N, CH, C provided that not more than 3 W groups are N in both rings A, B together; P = aminosulfonyl, sulfonamido, etc.; X, Y = H, halo, alkyl, CF3, etc.; R3 = piperazinyl, etc.] are prepared For instance, 6-benzenesulfonyl-4-chloroquinoline is reacted with piperazine (CH3CN, 80°, overnight) to give II isolated as the HCl salt. II has Ki = 10 nM for the human 5-HT6 receptor. I are useful for the treatment of conditions relating to obesity, type II diabetes and CNS disorders.

IT 636997-89-2P, tert-Butyl 4-[3-[(4-tert-butylphenyl)thio]quinolin-5-yl]-1,4-diazepane-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphthelene and pyridino-fused heterocycles useful for the treatment of obesity, type II diabetes and CNS disorders)

RN 636997-89-2 CAPLUS

CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[3-[[4-(1,1-dimethylethyl)phenyl]thio]-5-quinolinyl]hexahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:777764 CAPLUS
DN 139:292163
TI Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders
IN Ahmed, Mahmood; Johnson, Christopher Norbert; Jones, Martin C.; MacDonald, Gregor James; Moss, Stephen Frederick; Thompson, Mervyn; Wade, Charles Edward; Witty, David
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080580	A2	20031002	WO 2003-EP3197	20030325
	WO 2003080580	A3	20040205		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2479786	A1	20031002	CA 2003-2479786	20030325
	AU 2003219103	A1	20031008	AU 2003-219103	20030325
	EP 1497266	A2	20050119	EP 2003-714889	20030325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008696	A	20050125	BR 2003-8696	20030325
	CN 1656075	A	20050817	CN 2003-811644	20030325
	JP 2005531518	T	20051020	JP 2003-578335	20030325
	TW 268928	B	20061221	TW 2003-92106558	20030325

	RU 2309154	C2	20071027	RU 2004-131641	20030325
	ZA 2004007320	A	20051004	ZA 2004-7320	20040912
	IN 2004DN02703	A	20070302	IN 2004-DN2703	20040914
	MX 2004PA09318	A	20050125	MX 2004-PA9318	20040924
	US 2005124628	A1	20050609	US 2004-509078	20040927
	NO 2004004588	A	20041025	NO 2004-4588	20041025
PRAI	GB 2002-7289	A	20020327		
	GB 2002-25678	A	20021104		
	WO 2003-EP3197	W	20030325		

OS MARPAT 139:292163

GI



I

AB Title compds. I [R1, R2 = H, alkyl; R1R2, R22 = (CH2)2-4; R3-R5 = H, halogen, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, (un)substituted CONH2; A = (un)substituted aryl; m = 1-4; n = 1-3, p = 1, 2] were prepared for use as HT6 receptor antagonists in treatment of CNS disorders. Thus, 8-iodo-3-phenylsulfonylquinoline was prepared from 8-nitroquinoline and was treated with 1-tert.-butoxycarbonylpiperazine, followed by deblocking, to give 3-phenylsulfonyl-8-piperazinoquinoline.

IT 607743-10-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)

RN 607743-10-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-(phenylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



=> d l4 7-8 hitstr

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 847727-11-1P, 3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(1-piperazinyl)quinoline monohydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of piperazinylquinolines for treatment of CNS disorders)
RN 847727-11-1 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 847727-12-2P, 3-[(5-Fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-8-(1-piperazinyl)quinoline monohydrochloride 847727-15-5P, 3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(4-methyl-1-

piperazinyl)quinoline monohydrochloride 847727-16-6P,
3-[(2,3-Dihydro-1H-indol-1-yl)sulfonyl]-8-(1-piperazinyl)quinoline
847727-17-7P, 3-[(5-Fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-
8-(1-piperazinyl)quinoline 847727-20-2P, 3-[(2,3-Dihydro-1H-
indol-1-yl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of piperazinylquinolines for treatment of CNS
disorders)

RN 847727-12-2 CAPLUS
CN 1H-Isoindole, 5-fluoro-2,3-dihydro-2-[[8-(1-piperazinyl)-3-
quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847727-15-5 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(4-methyl-1-piperazinyl)-3-
quinolinyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 847727-16-6 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 847727-17-7 CAPLUS
CN 1H-Isoindole, 5-fluoro-2,3-dihydro-2-[[8-(1-piperazinyl)-3-quinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 847727-20-2 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[8-(4-methyl-1-piperazinyl)-3-quinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 847727-30-4P, 1,1-Dimethylethyl 4-[3-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-8-quinolinyl]-1-piperazinecarboxylate 847727-31-5P, 1,1-Dimethylethyl 4-[3-[(5-fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-8-quinolinyl]-1-piperazinecarboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperazinylquinolines for treatment of CNS disorders)

RN 847727-30-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847727-31-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)sulfonyl]-8-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
IT 636997-89-2P, tert-Butyl 4-[3-[(4-tert-butylphenyl)thio]quinolin-5-yl]-1,4-diazepane-1-carboxylate 636997-90-5P, tert-Butyl 4-[3-[(4-isopropylphenyl)thio]quinolin-5-yl]-1,4-diazepane-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphthelene and pyridino-fused heterocycles useful for the treatment of obesity, type II diabetes and CNS disorders)
RN 636997-89-2 CAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[3-[[4-(1,1-dimethylethyl)phenyl]thio]-5-quinolinyl]hexahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 636997-90-5 CAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-[3-[[4-(1-methylethyl)phenyl]thio]-5-quinolinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




```
=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    82.27     260.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -7.20      -7.20

FILE 'CAOLD' ENTERED AT 16:32:58 ON 06 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REGistRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> s l3
L5            0 L3

=> file chemcats
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.46     261.30
```

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                  0.00      -7.20

FILE 'CHEMCATS' ENTERED AT 16:33:09 ON 06 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)


FILE LAST UPDATED 22 DECEMBER 2007 (20071222/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow
prompt.  For the list of suppliers currently in the file, enter
HELP SPA, HELP SPB, HELP SPC, HELP SPDH, HELP SPIN, HELP SPOP, and
HELP SPQZ.  For the list of current catalogs, enter HELP CTA, HELP
CTB, HELP CTC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis.  Please consult the
suppliers for current information regarding pricing, regional
availability, available quantities, purities, etc.  THERE ARE NO
WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED.  ACS is not
liable for any loss of profit, goodwill or any other damages arising
out of the use of this database.

CHEMCATS now contains more than 17 million records.  See HELP CONTENT
and NEWS FILE for details.

=> s l3
L6            0 L3

=> log h
COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                  0.94     262.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                  0.00      -7.20

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:33:19 ON 06 JAN 2008
```